The imbalance between Th2 and Treg cells plays fundamental role in the pathogenesis of allergic asthma. The current study aimed at assessing the expression of some Th2 and Treg cell-related parameters in patients with allergic asthma. Material and Methods: The serum and peripheral blood mononuclear cell (PBMC) samples were collected from 30 patients with asthma and 36 healthy subjects. The serum levels of transforming growth factor (TGF)-β, interleukin (IL)-4, as well as the expression levels of GATA3 and FOXP3 genes in PBMCs were determined by the enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (PCR), respectively. The PBMCs were cultured for 48 hours with/without phytohemagglutinin (PHA) stimulation. The TGF-β and IL-4 levels in supernatants were also determined. Results: The serum levels of IL-4, the expression level of GATA3, and GATA3/FOXP3 ratio in patients with asthma were significantly higher than healthy subjects (P <0.002, P <0.001, and P <0.004, respectively). The FOXP3 expression did no differ between the two groups. The serum level of TGF-β as well as its secretion profile in non-stimulated and stimulated PBMCs isolated from patients with asthma were significantly higher than those of the controls (P <0.03, P <0.001, and P <0.001, respectively). The serum TGF-β levels in severe asthma were significantly higher than moderate asthma; whereas the TGF-β secretion by PHA-stimulated PBMCs isolated from moderate asthma was higher than that of severe pattern of the disease (P <0.001 and P <0.05, respectively). The GTAT3/FOXP3 expression ratio in moderate asthma was significantly higher than severe form (P <0.04).
The Treg cells constitute 5% to 15% of the total circulating CD4 + T lymphocytes divided into two subsets.
The natural Tregs (nTreg) cells are generated in the thymus, whereas the induced Treg (iTreg) cells are differentiated from peripheral CD4 + T lymphocytes after antigenic recognition and the existence of IL-2 and TGF-β (13, 14) . The immunosuppressive effects of Treg cells are exerted by releasing TGF-β, IL-10, and IL-35 that are necessary to establish tolerance to self-constituents or foreign antigens (13, 15) . The FOXP3 protein is considered as a master transcriptional factor of Treg cells and its gene is mapped to the X chromosome (15, 16 (17) .
There is evidence indicating that Th2/Treg imbalance plays an essential role in the development of allergic sicknesses (18) . The results of a number studies indicated that the count of Th2 cells was enhanced, while the count of Treg cells was diminished in the peripheral blood of patients with asthma or in the models of experimentallyinduced allergic asthma, representing the contribution of the Th2/Treg imbalance in the pathogenesis of allergic asthma (7, 19) . with asthma (19, 20) , while others reported elevated levels of this cytokine in the patients (21) (22) (23) . Moreover, the exact association of Th2 and Treg cell-related parameters with asthma severity is still unclear.
The current study aimed at determining the key parameters of Th2 (IL-4 and GATA3) and Treg (TGF-β and To normalize the amplified cytokine target genes, the - 
The serum and PBMC supernatant levels of TGF-β and IL-4
The serum and PBMC supernatant levels of TGF-β and IL-4 were quantified using commercial ELISA (the enzyme-linked immunosorbent assay) kits for human TGF-β and IL-4 (eBioscience, USA).
Serum IgE concentrations
Serum total IgE concentrations (IU/mL) were measured by the commercial ELISA kit (Monobind Inc., Costa Mesa, CA, USA).
Statistical analysis
Data were expressed as mean ± standard error of the mean (SEM). Differences in variables were analyzed by appropriate statistical tests including ANOVA, the Student t, Kruskal-Wallis, and Mann-Whitney U tests; P values <0.05 were regarded statistically significant.
RESULTS
The mean age of the patients with asthma and the healthy subjects were 36. 
Serum levels of TGF-β and IL-4 in patients with asthma and healthy controls
The serum levels of TGF-β and IL-4 were significantly higher in patients with asthma than the healthy controls (321.70 ± 35.12 vs. 226.69 ± 17.81 pg/mL, P <0.03 and 1.66 ± 0.05 vs 1.42 ± 0.04 pg/mL, P <0.002; respectively) ( Figures   1 and 2 ). The serum levels of TGF-β were higher in patients with severe asthma (484.25±120.73 pg/mL) than the ones with moderate asthma (281.07±27.31 pg/mL, P <0.02) and healthy controls (226.69±17.81 pg/mL, P <0.001). There was no significant difference in terms of the serum level of TGF-β between patients with moderate asthma and healthy controls, although the parameter was higher in patients with moderate asthma (P=0.10) (Figure 3 ).
The serum levels of IL-4 in patients with moderate (1.66±0.06 pg/mL) and severe asthma (1.66 ± 0.10 pg/mL)
were significantly higher than that of the healthy controls The serum TGF-β levels of asthmatic were significantly higher than in healthy subjects. The serum IL-4 levels in patients with asthma were significantly higher than in healthy subjects. The serum TGF-β levels in patients with severe asthma were significantly higher than in patients with moderate asthma and healthy subjects. 
The FOXP3 and GATA3 expression and their ratio in PBMCs isolated from patients with asthma and healthy individuals
The GATA3 expression in PBMCs isolated from patients with asthma was significantly higher than that of the healthy subjects (3.30±0.51 vs. 1.15±0.10, P<0.001). The FOXP3 expression in PBMCs isolated from patients with asthma was also higher than that of the healthy subjects, but the difference was not significant (2.15±0.76 vs.
1.01±0.11, P=0.10). GATA3/FOXP3 ratio in PBMCs isolated
from patients with asthma was significantly higher than that of healthy subjects (9.49±2.02 vs. 3.48±0.78, P<0.004).
The expression of GTAT3 in PBMCs isolated from patients with moderate (3.50±0.64) and severe asthma (2.60±0.51) were significantly higher than that of the healthy controls (P<0.001 and P<0.02, respectively). There was no significant difference in terms of GATA3 expression between patients with moderate and severe asthma ( Figure 5 ).
The expression of FOXP3 in PBMCs isolated from patients with moderate asthma (2.33±0.90) was higher than that of the ones with severe asthma (1.12±0.33) as well as the healthy subjects, but the differences were not statistically significant ( Figure 6 ).
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The GTAT3 expression in both patient groups with moderate-and severe asthma were significantly higher than healthy control group. The FOXP3 expression in patients with moderate asthma was higher than those with severe asthma and also healthy subjects, but the differences were not significant. The GTAT3/FOXP3 expression ratio in PBMCs isolated from patients with moderate asthma (11.09 ± 2.50) was significantly higher than that of the patients with severe asthma (3.90 ± 1.22) and the healthy controls (3.48 ± 0.78), (P<0.04 and P <0.01, respectively). There was no significant difference in terms of GTAT3/FOXP3 expression ratio between patients with severe asthma and healthy subjects ( Figure 7 ).
The expression of GATA3/FOXP3 ratio in patients with moderate asthma was significantly higher than in patients with severe asthma and healthy subjects. Table 2 . In both groups of healthy subjects and patients with asthma, TGF-β and IL-4 production by PHA-stimulated PBMCs were significantly higher than those of the unstimulated cells (P <0.05 and P <0.001, respectively) (Figures 8 and 9 ).
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In both healthy-and asthmatic groups, the PHA-induced TGF-β secretion were significantly higher than nonstimulated culture. The levels of TGF-β production by non-stimulated and PHA-stimulated PBMCs from patients with asthma were significantly higher than in the same cultures from healthy subjects. Figure 8 . TGF-β production by non-stimulated and PHA-stimulated PBMCs from the healthy group and asthmatic patients.
In both healthy-and asthmatic groups, the PHA-induced IL-4 secretion were significantly higher than nonstimulated culture. The levels of IL-4 production by non-stimulated PBMCs from patients with asthma were significantly higher than in the same cultures fromhealthy subjects. The levels of TGF-β and IL-4 production by nonstimulated PBMCs in patients with asthma were significantly higher than those of healthy controls (P <0.001
and P <0.03, respectively) (figures 8 and 9). Moreover, the production of PHA-stimulated TGF-β by PBMCs isolated from patients with asthma was significantly higher than that of healthy controls (P <0.001) (Figure 8 ). There was no significant difference in terms of the production of PHAstimulated IL-4 between patients and healthy individuals, although the parameter was higher in patients groups (P=0.34) (Figure 9 ).
The production of TGF-β by unstimulated and PHAstimulated PBMCs isolated from patients with moderate asthma were higher than those of the ones with severe asthma, although the difference was significantly higher in PHA-stimulated cells (P <0.05) ( Table 2 ). No significant difference was observed between patients with moderate and severe asthma regarding the production of IL-4 by non-stimulated and PHA-stimulated PBMCs (Table 2 ).
There was no significant difference between males and females in patients or in the control groups regarding the production of TGF-β and IL-4 by unstimulated and PHAstimulated PBMCs (Table 3) . 
DISCUSSION
The results of the current study indicated that the serum level of IL-4 and GATA3 expression were The results of the current study also indicated that GATA3/FOXP3 expression ratio in patients with asthma was significantly higher than those of healthy individuals. introduce novel therapeutic agents to modulate inflammation in patients with asthma.
The current study results also demonstrated that in both patients with moderate and severe asthma, serum levels of IL-4 and GTAT3 expression were higher than those of the healthy individuals. There were no significant differences in serum levels of IL-4 and GATA3 expression between patients with moderate and severe asthma. These results indicated that the Th2 immune responses contribute to the pathogenesis of both moderate and severe patterns of allergic asthma.
The results of the current study also indicated that the serum levels of TGF-β in patients with severe asthma were higher than those of the ones with moderate asthma.
However, in controversy to serum levels of TGF-β, the production of this cytokine by PHA-stimulated PBMCs isolated from patients with moderate asthma was higher than that of the ones with severe asthma. These differences may be attributed to different in vivo cell producers of TGF-β. As mentioned above, TGF-β is produced by some The serum level of TGF-β in patients with severe asthma was higher than that of the ones with moderate asthma, whereas the TGF-β production by PHA-stimulated
PBMCs isolated from patients with moderate asthma was also higher than that of the patients with severe asthma.
The current study results showed that TGF-β may have different effects on moderate and severe asthma.
GTAT3/FOXP3
expression ratio in patients with moderate asthma was significantly higher than that of the ones with severe asthma. Therefore, moderate and severe asthma may have significant differences in some main immunological parameters.
